首页> 外文期刊>Heart >Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension
【24h】

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension

机译:Rho激酶抑制剂法舒地尔对严重肺动脉高压患者的急性血管扩张作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Pulmonary hypertension (PH) is characterised by progressive elevation of pulmonary artery pressure and pulmonary vascular resistance. Pathohistological findings have demonstrated that PH is associated with abnormal vascular structures, including medial and/or intimal hypertrophy, concentric or eccentric intimal fibrosis, obstruction in the arterial lumen, and aneurysmal dilatation. Patients with PH are currently treated with anticoagulant agents, vasodilators including continuous intravenous prostacyclin (pros-taglandin I_2) and oral sildenafil or bosentan, and in end stage, with lung transplantation, when applicable. Endothelial dysfunction of pulmonary arteries and enhanced pulmonary vasoconstriction contribute to the development of PH. Endothelial nitric oxide synthase (eNOS) expression is reduced in patients with PH and therefore nitric oxide inhalation and sildenafil are useful for those patients. However, more effective treatments remain to be developed. We have recently demonstrated that Rho-kinase is substantially involved in the pathogenesis of a wide range of cardiovascular disease. Rho-kinase suppresses myosin phosphatase activity by phosphorylating the myosin binding subunit of the enzyme and thus augments vascular smooth muscle cell (VSMC) contraction at a given intracellular calcium concentration. Indeed, we have demonstrated that a Rho-kinase inhibitor, fasudil, suppresses abnormal hyper-constriction of forearm and coronary arteries in animals and humans. Moreover, we have recently demonstrated that Rho-kinase inhibition increases eNOS expression and decreases inflammatory cell migration or anigiotensin II induced mRNA expression of monocyte chemoattractant protein-1 and plasminogen activator inhibitor-1 in vivo and in vitro. Our in vivo study also indicated that long term oral treatment with fasudil notably ameliorates monocrotaline induced PH and pulmonary vascular lesions in rats. In the present study, we thus examined the acute vasodilatory effects of pulmonary circulation by intravenous administration of fasudil in patients with severe PH.
机译:肺动脉高压(PH)的特征是肺动脉压和肺血管阻力逐渐升高。病理组织学发现表明,PH与异常的血管结构有关,包括内侧和/或内膜肥大,同心或离心内膜纤维化,动脉管腔阻塞和动脉瘤扩张。目前,患有PH的患者接受抗凝剂,血管扩张剂(包括连续静脉内前列环素(pros-taglandin I_2)和西地那非或波生坦)的治疗,并在最终阶段进行肺移植(如果适用)。肺动脉的内皮功能障碍和增强的肺血管收缩促进了PH的发展。患有PH的患者内皮一氧化氮合酶(eNOS)的表达降低,因此吸入一氧化氮和西地那非对这些患者有用。但是,仍有待开发更有效的治疗方法。最近,我们证明了Rho激酶实质上参与了广泛的心血管疾病的发病机制。 Rho激酶通过使酶的肌球蛋白结合亚基磷酸化来抑制肌球蛋白磷酸酶的活性,从而在给定的细胞内钙浓度下增加血管平滑肌细胞(VSMC)的收缩。实际上,我们已经证明,Rho激酶抑制剂fasudil可以抑制动物和人体内前臂和冠状动脉的异常过度收缩。此外,我们最近已经证明,在体内和体外,Rho激酶抑制作用可增加eNOS的表达并减少炎症细胞迁移或血管紧张素II诱导的单核细胞趋化蛋白1和纤溶酶原激活物抑制剂1的mRNA表达。我们的体内研究还表明,用法舒地尔进行长期口服治疗可显着改善单芥子碱诱导的大鼠PH和肺血管病变。因此,在本研究中,我们通过静脉注射法舒地尔对重度PH患者的肺循环的急性血管舒张作用进行了检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号